Costunolide derivatives

Details Costunolide derivatives Costunolide derivatives

2008-12-16

2009-11-24

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S470000, C514S320000

Reexamination Certificate

active

07622465

ABSTRACT:
Disclosed are methods for inhibiting TNFα expression, IL-1β expression, iNOS expression, and NF-κB activity and methods for treating autoimmune disease, cancer, or atherosclerosis with a compound of the following formula:

REFERENCES:
patent: 5905089 (1999-05-01), Hwang et al.
patent: 2005/0272716 (2005-12-01), Crooks et al.
Synthesis of melampolides and cis,cis-germacranolides as natural herbicide models; Francisco A. Macias, Raul F. Velasco, Jose A. Alvarex, Diego Castellano and Juan C.G. Galindo; 2004 Elsevier Ltd.; 8477-8488.
Kang et al., “Costunolide Inhibits Interleukin-1β Expression by Down-Regulation of AP-1 and MAPK Activity in LPS-Simulated RAW 264.7 Cells,” Biochemical and Biophysical Research Communication, 313:171-177 (2004).
Macias et al. Tetrahedron (2004), 60(38), 8477-8488.
Choi et al. STN Accession Number: 2002:935701, Document No. 138:378745, Abstract of Biological & Pharmaceutical Bulletin (2002), 25(11), 1446-1450.
El-Feraly, STN Accession No: 1985:21216, Document No. 102:21216, Abstract of Phytochemistry (Elsevier) (1984), 23(10), 2372-4.

Affiliated with

Also associated with

Rating

Costunolide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Costunolide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Costunolide derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4137171